NASDAQ:VIR - Vir Biotechnology Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $66.00
  • Forecasted Upside: 34.39 %
  • Number of Analysts: 7
  • Breakdown:
  • 2 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
▲ +2.96 (6.41%)

This chart shows the closing price for VIR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vir Biotechnology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VIR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VIR

Analyst Price Target is $66.00
▲ +34.39% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Vir Biotechnology in the last 3 months. The average price target is $66.00, with a high forecast of $135.00 and a low forecast of $24.00. The average price target represents a 34.39% upside from the last price of $49.11.

This chart shows the closing price for VIR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 7 contributing investment analysts is to hold stock in Vir Biotechnology. This rating has held steady since October 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 2 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/16/2021Needham & Company LLCReiterated RatingBuy$80.00High
3/8/2021HC WainwrightBoost Price TargetBuy$125.00 ➝ $135.00Low
3/8/2021Needham & Company LLCBoost Price TargetBuy$75.00 ➝ $80.00N/A
3/3/2021The Goldman Sachs GroupBoost Price TargetBuy$59.00 ➝ $61.00High
3/2/2021Needham & Company LLCBoost Price TargetBuy$62.00 ➝ $75.00High
2/25/2021BarclaysBoost Price TargetPositive ➝ Overweight$61.00 ➝ $77.00High
1/27/2021JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$30.00High
1/20/2021HC WainwrightBoost Price TargetBuy$100.00 ➝ $125.00Medium
12/25/2020Robert W. BairdReiterated RatingSell$24.00N/A
12/24/2020Robert W. BairdReiterated RatingSell$24.00N/A
10/7/2020HC WainwrightBoost Price TargetBuy$80.00 ➝ $100.00Low
10/5/2020Bank of AmericaInitiated CoverageBuy$55.00 ➝ $55.00High
9/21/2020HC WainwrightBoost Price TargetBuy$75.00 ➝ $80.00High
9/14/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy$48.00 ➝ $54.00Low
9/11/2020JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$30.00 ➝ $29.00Low
8/31/2020The Goldman Sachs GroupBoost Price TargetNeutral$43.00 ➝ $48.00High
8/24/2020HC WainwrightReiterated RatingBuy$75.00High
8/20/2020Needham & Company LLCInitiated CoverageBuy$62.00Medium
8/12/2020BarclaysBoost Price TargetOverweight$44.00 ➝ $61.00Low
5/13/2020BarclaysBoost Price TargetOverweight$41.00 ➝ $44.00High
3/29/2020BarclaysReiterated RatingBuy$41.00High
3/27/2020Robert W. BairdBoost Price TargetUnderperform$17.00 ➝ $20.00Medium
3/19/2020JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$26.00High
3/13/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$37.00High
2/27/2020Robert W. BairdDowngradeNeutral ➝ Underperform$17.00High
2/4/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$25.00 ➝ $26.00Low
11/19/2019CowenInitiated CoverageBuyMedium
11/13/2019Robert W. BairdInitiated CoverageNeutralLow
11/5/2019The Goldman Sachs GroupInitiated CoverageBuy$37.00Medium
11/5/2019BarclaysInitiated CoverageOverweight$25.00Medium
11/5/2019JPMorgan Chase & Co.Initiated CoverageOverweight$25.00Medium
11/5/2019CowenInitiated CoverageOutperformMedium
(Data available from 6/21/2016 forward)
Vir Biotechnology logo
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $49.11
Low: $45.43
High: $49.29

50 Day Range

MA: $44.96
Low: $38.75
High: $51.00

52 Week Range

Now: $49.11
Low: $25.31
High: $141.01


931,450 shs

Average Volume

1,359,303 shs

Market Capitalization

$6.39 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Vir Biotechnology?

The following Wall Street research analysts have issued stock ratings on Vir Biotechnology in the last year: Bank of America Co., Barclays PLC, HC Wainwright, JPMorgan Chase & Co., Needham & Company LLC, Robert W. Baird, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for VIR.

What is the current price target for Vir Biotechnology?

7 Wall Street analysts have set twelve-month price targets for Vir Biotechnology in the last year. Their average twelve-month price target is $66.00, suggesting a possible upside of 34.4%. HC Wainwright has the highest price target set, predicting VIR will reach $135.00 in the next twelve months. Robert W. Baird has the lowest price target set, forecasting a price of $24.00 for Vir Biotechnology in the next year.
View the latest price targets for VIR.

What is the current consensus analyst rating for Vir Biotechnology?

Vir Biotechnology currently has 2 sell ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in VIR, but not buy more shares or sell existing shares.
View the latest ratings for VIR.

What other companies compete with Vir Biotechnology?

How do I contact Vir Biotechnology's investor relations team?

Vir Biotechnology's physical mailing address is 499 ILLINOIS STREET SUITE 500, SAN FRANCISCO CA, 94158. The company's listed phone number is 415-906-4324 and its investor relations email address is [email protected] The official website for Vir Biotechnology is